CLAIM #18462 · CVS Health Corp (CVS) · 2024Q3 earnings call · Nov 6, 2024 · due Dec 31, 2025
“Our early indicators would suggest that we would be down in that size of 10% range on the total book.”
Tom Cowhey · CFO
In context
“, the level of confidence that you have around the bids that you did put in for 2025, if I could understand that. Then just secondly, you talked about pharmacy, we’ve heard others talk about pharmacy trends here in the back half of the year really shifting and changing because of the Inflation Reduction Act and changes around kind of [indiscernible] coverage. Just curious, one, did you see that as well specific to those changes, and is it benefiting perhaps some of the other sides of your business? I know obviously you have a really big specialty business and you talked about the strength in the pharmacy business. Tom Cowhey: Let me start with your first question. We’re early in the open enrollment season, but I did reiterate the guidance that we’ve been giving for a couple of months now. Our early indicators would suggest that we would be down in that size of 10% range on the total book. We’ll have more stability on the group book, so that’s a higher percentage as you think about the individual and the dual eligible populations that we’ll see declines on, but we feel reasonably good about how the membership is coming in and that it would be within that range that we’ve been guiding investors to. As you think about ability and confidence in the bids, the bids are clearly designed to improve results next year, and maybe there’s a couple of things I can talk you through at a high level, just to give you a framework to think about that. The first is improvement in stars, and so because of the contracts that we have that are now going to be four stars or better for 2025 payment year, that’s going to be about an $800 million headwind, no matter what the baseline is--or excuse m”
Verify independently
SEC filings for CVS ↗ · Claim quote is verbatim from the 2024Q3 earnings call.